Immunovant Inc. (IMVT)
IMVT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$28.71
-2.61% on the day
Market cap
$5.9B
Mid cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | IMVT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001764013 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-12 |
| Latest annual report | 10-K | 2026-05-20 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-09-03 |
| Latest proxy | DEFA14A | 2026-07-22 |
Source: SEC EDGAR submissions feed, 646 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -12.6% |
| 1 month | -23.6% |
| 3 months | -28.1% |
| Year to date | +10.1% |
| 1 year | +61.4% |
| From 52-week high | -37.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc | $91.63 | -7.69% | $5.8B |
| CGON | CG Oncology Inc. | $62.40 | -1.16% | $5.5B |
| IOVA | Iovance Biotherapeutics Inc. | $14.50 | -0.41% | $6.6B |
| SRRK | Scholar Rock Holding Corporation | $40.52 | -3.39% | $4.9B |
| CRSP | CRISPR Therapeutics AG Common Shares | $50.10 | -2.81% | $4.8B |
| RGEN | Repligen Corporation | $175.42 | +1.69% | $8.6B |
| ADPT | Adaptive Biotechnologies Corporation | $25.28 | -1.13% | $4.0B |
| KYMR | Kymera Therapeutics Inc. | $106.68 | -4.82% | $8.9B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier